Stockscreener 앱 받기
184.18
0.00%
0.00
시장 영업 전:
184.43
0.25
+0.14%
전일 마감가:
$184.18
열려 있는:
$184.18
하루 거래량:
540.40K
Relative Volume:
0.88
시가총액:
$9.42B
수익:
$638.50M
순이익/손실:
$-183.17M
주가수익비율:
-49.86
EPS:
-3.6943
순현금흐름:
$-93.89M
1주 성능:
+6.35%
1개월 성능:
+18.00%
6개월 성능:
+42.14%
1년 성능:
+77.39%
1일 변동 폭
$179.57
$185.05
1주일 범위
$172.02
$185.05
52주 변동 폭
$96.09
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
184.18 | 9.42B | 638.50M | -183.17M | -93.89M | -3.6943 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
axsm stock overview: Axsome Therapeutics (AXSM) - Bitget
AXSM SEC FilingsAxsome Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Maintains Axsome Therapeutics (AXSM) Buy Recommendation - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo Finance
Update Recap: How does Axsome Therapeutics Inc compare to its peers2026 Outlook & AI Forecasted Stock Moves - baoquankhu1.vn
Axsome Is Priced For Perfection Ahead Of Auvelity's Alzheimer's Agitation Decision - Seeking Alpha
Iridian Asset Management LLC CT Sells 9,770 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Aug Big Picture: Does Axsome Therapeutics Inc outperform in volatile markets2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge - Yahoo Finance
Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test - Yahoo Finance
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Axsome Therapeutics (AXSM) Is Up 6.2% After Highlighting Key FDA Decision on Auvelity - simplywall.st
Today's Analyst Ratings for Axsome Therapeutics (AXSM) | AXSM St - GuruFocus
UBS Group Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says - marketscreener.com
UBS raises Axsome Therapeutics price target on Auvelity outlook By Investing.com - Investing.com Canada
UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from Takeda - Legal Desire Media and Insights
Franklin Street Advisors Inc. NC Invests in Axsome Therapeutics - National Today
Why Axsome Therapeutics Stock Is Suddenly Sinking - TipRanks
Franklin Street Advisors Inc. NC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 - Sahm
Axsome’s Decade of 33% Returns Puts Focus on $16 Billion Pipeline - NAI500
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Is This Healthcare Stock a Millionaire Maker? - AOL.com
(AXSM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics (AXSM) Q2 2024 earnings summary - Quartr
AXSM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda - Sahm
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Acquisition Play Signals A Bold Push Into Schizophrenia Market! - Smartkarma
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome Acquires Global Rights to TAK-063 from Takeda - Intellectia AI
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $260 - Moomoo
Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor balipodect - The Pharma Letter
AXSM Technical Analysis & Stock Price Forecast - intellectia.ai
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions - Sahm
Biopharma bites: Axsome adds an asset from Takeda, IO Biotech's farewell, and Evotec's new commercial leader - FirstWord Pharma
Takeda (TAK) Sells Rights to Schizophrenia Drug to Axsome - GuruFocus
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Axsome Therapeutics Acquires Global Rights to Balipodect, a Selective PDE10A Inhibitor, for Schizophrenia and Neuropsychiatric Disorders 1 - minichart.com.sg
Axsome acquires global rights to Takeda’s balipodect - TipRanks
Axsome acquires global rights to balipodect from Takeda By Investing.com - Investing.com Canada
Axsome Therapeutics Acquires Exclusive Global Rights to Balipodect from Takeda - marketscreener.com
Axsome Therapeutics acquires balipodect, gains global rights and plans Phase 3-enabling work for schizophrenia - TradingView — Track All Markets
Axsome acquires global rights to balipodect from Takeda - Investing.com
Axsome Therapeutics (NASDAQ: AXSM) secures global rights to balipodect - Stock Titan
Axsome Therapeutics Incto Begin Phase 3 Tr - Moomoo
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):